OOIR: Observatory of International Research

Papers

(The TQCC of British Journal of Haematology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Issue Information	105
e‐Posters	87
Don't forget cord blood in non‐remission acute myeloid leukaemia!	81
Issue Information	75
A 4‐gene prognostic index for enhancing acute myeloid leukaemia survival prediction	69
Immunophenotypic clustering in paediatric acute myeloid leukaemia	67
Issue Information	59
Correction to “Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients”	58
	52
Venetoclax ramp‐up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study	51
Population pharmacokinetics of high‐dose methotrexate and 7‐hydroxy methotrexate in Chinese adults with primary central nervous system lymphoma	49
Granulocyte colony‐stimulating factor may improve engraftment in adults with sickle cell disease undergoing non‐myeloablative haematopoietic stem cell transplantation	45
Unveiling the responsible antigen in vaccine‐induced immune thrombotic thrombocytopenia	45
The role of genetics in refractory immune thrombocytopenia	43
Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial	42
The significance of mixed chimaerism and cell lineage chimaerism monitoring in paediatric patients post haematopoietic stem cell transplant	40
Would you like to take some more ruxolitinib after your fedratinib?	39
Efficacy of ciclosporin monotherapy in non‐severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study	38
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia	38
Promises and challenges of artificial intelligence in haematological diagnostics	36
Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline	35
The impact of COVID‐19 vaccination on patients with a history of heparin‐induced thrombocytopenia	35
CAR T in patients with large B‐cell lymphoma not fit for autologous transplant	35
Quality of life in childhood immune thrombocytopenia: Revision of the Kids' ITP Tools (KIT)	35
Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lympho	35

Clinical outcomes and safety in patients with lower‐risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial	35
How to dose and monitor argatroban for treatment of HIT	34
Prolonged platelet hyperactivity after COVID‐19 infection	33
Whole‐exome sequencing uncovered genetic diagnosis of severe inherited haemolytic anaemia: Correlation with clinical phenotypes	33
ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non‐myeloablative conditioning	33
R‐CHOP treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of JCOG0203	33
Clinical perspectives on post‐induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation	33
Haematopoietic stem cell mobilisation followed by high‐dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma	32
Functional impairment of erythropoiesis in Congenital Dyserythropoietic Anaemia type I arises at the progenitor level	32
Myelodysplastic syndrome associated‐haemophagocytic lymphohistiocytosis: A retrospective study of 15 cases in a single centre	32
Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation	31
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia	29
Immune‐mediated thrombocytopenia and IL‐6‐mediated thrombocytosis observed in idiopathic multicentric Castleman disease	29
	28
Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross‐sectional survey	28
The oldest case of lymphoma? Insights from a XIII century fresco	28
Phase Ib study of eltrombopag and azacitidine in patients with high‐risk myelodysplastic syndromes and related disorders (the ELASTIC study)	28
Management of immunosuppression in post‐transplant lymphoproliferative disorders treated with CAR T cells	28
Assessment of intrathecal therapy in the treatment of familial haemophagocytic lymphohistiocytosis	27
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukoc	27
Concomitant HIV‐associated plasmablastic lymphoma and visceral leishmaniasis at initial presentation	27
Outcomes and risk factors of second allogeneic haematopoietic stem cell transplantation in patients with relapsed haematological malignancy after first transplantation	26
Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore)	25
Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma – A study from the Danish Lymphoma Registry	25
Immune thrombocytopenia (ITP) in pregnancy	25
No benefit from daratumumab, bortezomib and dexamethasone (D‐Vd) in real‐world patients with functional high‐risk multiple myeloma: A report from the Myeloma and Related Diseases Registry	25
SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T‐cell neoplasms	25
Evaluating the impact of thrombopoietin receptor agonist medications on patient outcomes and quality of life in paediatric immune thrombocytopenia through semi‐structured interviews	24
How I manage myeloproliferative neoplasm‐unclassifiable: Practical approaches for 2022 and beyond	23
Screening for monoclonal gammopathy of undetermined significance is contraindicated	23
Inhibition of the Sec61 translocon overcomes cytokine‐induced glucocorticoid resistance in T‐cell acute lymphoblastic leukaemia	23
Long‐term outcome after allogeneic stem cell transplantation for GATA2 deficiency: An analysis of 67 adults and children from France and Belgium	23
Lower anti‐spike levels in B‐cell‐depleted patients after convalescent plasma transfusion suggest the need for repeated doses	23
Indirect presentation of mismatched human leukocyte antigen ‐B associates with outcomes of cord blood transplantation	23
A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complet	23
Are there long‐term effects of combination therapy for newly diagnosed adults with ITP ?	22
The impact of JAK2 ^V617F variant allele frequency in	22
Bone mineral density and vertebral fractures in teenage and young adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma: A report from the British Osteo	22
Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant	22
Chronic myelomonocytic leukaemia	22
Identification and management of preoperative anaemia in adults: A British Society for Haematology Guideline update	22
Can we move beyond myeloablative conditioning ( MAC )? A comparison of MAC versus reduced intensit	22
Association of biomarkers of endothelial function, coagulation activation and kidney injury with persistent albuminuria in sickle cell anaemia	22
Management of luspatercept therapy in patients with transfusion‐dependent β‐thalassaemia	22
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts	21
MYC‐induced cytidine metabolism regulates survival and drug resistance via cGas‐STING pathway in mantle cell lymphoma	21
Correction to ‘Personalized therapy guided by single‐cell transcriptomic analysis in relapsed and refractory KMT2A::MLLT10AML with extensive extramedullary infiltration: A	21
Evaluation of coverage, generalisability and validity of the U‐CAN lymphoma biobank in Sweden: A comparison with nationwide registers	21
A novel PML germline variant as a candidate predisposing genetic aberration in familial acute myeloid leukaemia	21
	21

Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients	21
Obituary Dr Christine Costello: MBChB, DRCOG, FRCP, FRCPath 29 August 1945–31 December 2021	21
Novel transferrin gene mutations in four new cases of congenital Atransferrinaemia: Functional and diagnostic pathogenicity despite negative bioinformatics	21
Empagliflozin modulates CD4⁺ T‐cell differentiation via metabolic reprogramming in immune thrombocytopenia	21
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline	21
Issue Information	21
Issue Information	21
Issue Information	21
Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma—Response	20
Beware clonal haematopoiesis following chronic lymphocytic leukaemia treatment	20
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia	20
Clinical decision support to reduce unnecessary diagnostic testing for heparin‐induced thrombocytopenia	20
Factor VII deficiency: A cause of (or risk factor for) bleeding?	20
A rare case of transformation from relapsed acute monocytic leukaemia with KMT2A::MLLT10 to acute megakaryoblastic leukaemia	20
Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T‐ALL	20
A single dose of eculizumab terminated life‐threatening haemolysis in idiopathic IgM‐mediated warm autoimmune haemolytic anaemia: A case report	20
Ganglioneuroblastoma with cannibalism in bone marrow	20
Relevance of the E756del common variant in the PIEZO1 gene for haemolytic anaemia and hepatic iron overload	19
Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome	19
Another side of IgA neoplastic plasma cells	19
Programmed cell death‐1 inhibition activates CD4 T cells in a novel in vitro model of Hodgkin lymphoma	19
	19
Exploratory study on the individualized application of eltrombopag in paediatric immune thrombocytopenia guided by therapeutic drug monitoring	19
Correction to “Refractory/relapse thrombocytopenia in a patient with Evans' syndrome successfully treated with zanubrutinib”LiM, LiuL, DingB, SongX, XiaA, HanY, et al. Refractory/relapse thrombocytope	19
Different clearance of KITD816V mutation and tryptase levels after haematopoietic cell transplantation in patients with systemic mastocytosis with associated haematological neoplasm	19
Assessment of neurocognitive functioning in sickle cell disease and thalassaemia and the association with silent cerebral infarcts, cerebral haemodynamics and oxygen metabolism	19
Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia	19
Autoimmune cytopenia and Kabuki syndrome in paediatrics: Insights in 11 patients	19
Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma	19
Erratum to: The HMG‐CoA inhibitor, simvastatin, triggers in vitro anti‐tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia	19
Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper	19
Hyperammonemia and acute liver failure associated with deferasirox in two adolescents with sickle cell disease	19
A synonymous variant is unmasked in thalassaemia	18
Cholesterol‐conjugated miR‐29b induces fetal haemoglobin expression via γ‐globin promoter demethylation in the Townes mouse model for sickle cell anaemia	18
Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study	18
Antibody response and intra‐host viral evolution after plasma therapy in COVID ‐19 patients pre‐exposed or not to B‐cell‐depleting agents	18
Enterococcus proliferates via the phosphotransferase system in the disrupted gut microbiota after allogeneic haematopoietic stem cell transplantation	18
Facing the bleeding risk of caplacizumab in postpartum immune thrombotic thrombocytopenic purpura in constrained resource settings	18
Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study	18
New cases expand the genotype, phenotype and therapeutic landscape of H syndrome	18
Toward a paradigm shift in prognostication and treatment of early‐stage Hodgkin lymphoma	18
Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia	18
A defined serum‐free culture system for human long‐term haematopoietic stem cells	18
Successful treatment of relapsed idiopathic multicentric Castleman disease–idiopathic plasmacytic lymphadenopathy with orelabrutinib monotherapy: A case report	18
Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I‐BFM Study	18
Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma	18
A treatment strategy to mitigate the adverse effect of pretransplant mogamulizumab on post‐transplant clinical outcome in patients with aggressive ATL	18
Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain—The Fostasur Study	17
Concurrence of mixed cryoglobulinaemia and cold agglutinin disease, and the putative role for a stereotyped immunoglobulin light chain	17
The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman‐like lymphadenopathies: A 20‐year retrospective analysis of clinical and pathological features	17
Decoding the molecular drivers of TP53 ‐mutant acute myeloid leukaemia: Clinical implications and prognostic insights	17
Evans syndrome in pregnancy and the postpartum period: A retrospective cohort study	17
Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up‐front autologous stem cell transplant	17
Recurrence after stopping anticoagulants in women with combined oral contraceptive‐associated venous thromboembolism: A systematic review and meta‐analysis	17
Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B‐ALL in CR1 with no detectable minimal residual disease	17
The effect of antinuclear antibody titre and its variation on outcomes in children with primary immune thrombocytopenia	17
Mutation spectrum of FLT3 and significance of non‐canonical FLT3 mutations in haematological malignancy	17
Urinary angiotensinogen is associated with albuminuria in adults with sickle cell anaemia	17
Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma — All StAGEs: A consensus‐based position paper from the Hodgkin lymphoma subgroup	17
Acute myeloid leukaemia with SRSF2 and BRAF mutations preceded by histiocytic proliferation in the bone ma	17
Risk of infections with bispecific antibodies in B‐cell non‐Hodgkin lymphomas and multiple myeloma—The current state	17
A CD38 / CD3xCD28 trispecific T‐cell engager as a potentially active agent in multiple myeloma pat	17
Time‐to‐event surrogate end‐points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis	16
Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia	16
Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR study	16
Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma	16
Issue Information	16
Successful combined anti‐CD19 immunotherapy of relapsed acute lymphoblastic leukaemia in a child with Nijmegen breakage syndrome	16
Patient survey in immune thrombocytopenia (ITP): Identifying unmet needs related to treatment and disease control in patients living in the United States	16
Inhibition of DOCK1 suppresses Notch signalling pathway and impairs leukaemogenesis	16
	16
	16
Ruxolitinib‐based regimen in children with autoimmune disease or autoinflammatory disease‐related haemophagocytic lymphohistiocytosis	16
Bone marrow necrosis and fat embolism in critically ill patients with acute complications of sickle cell disease: A retrospective cohort study	16
GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model	16
Prognostic value of CEBPA bZIP signatures in cytogenetically normal acute myeloid leukaemia	16
Association of human leucocyte antigen loci with vaccine‐induced immune thrombotic thrombocytopenia: Potential role of the interaction between platelet factor 4‐derived peptides and MHC‐	16
Fetal and neonatal alloimmune thrombocytopenia: No evidence of systemic inflammation as a modulator of disease severity. Could placental inflammation be key?	15
Issue Information	15
Multiple myeloma with acicular crystalline inclusion bodies	15

Dysplastic plasma cells in multiple myeloma	15
The impact of B‐cell‐directed therapy on SARS‐CoV‐2 vaccine efficacy in chronic lymphocytic leukaemia	15
Reframing thalassaemia syndrome as a benign haematopoietic stem cell disorder	15
Long‐term real‐world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all‐trans retinoic acid without chemotherapy—a retrospective, single‐centre study	15
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML‐001 trial	15
Issue Information	15
	15
Erratum	15
PF4 promotes CXCR3⁺ Tfh1 cell differentiation through STAT1 in mouse immune thrombocytopenia	15
Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T‐cell therapy: A CIBMTR analysis	15
Prognostic impact of FLT3‐ITD mutation on NPM1⁺ acute myeloid leukaemia patients and related molecular mechanisms	15
The usefulness of indium‐111 platelet scintigraphy beyond predicting efficacy of splenectomy	15
	15
Issue Information	15
	15
Spurious thrombocytosis, red cell count and mean cell volume in a patient with thermal burns	15
Proteomic analysis of neutrophils from patients with COVID‐19	15
Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia	15
CLOX and neurotox: Utility of the clock drawing task in monitoring for immune effector cell‐associated neurotoxicity syndrome following chimeric antigen receptor T‐cell therapy	14
How to discover the exceptional venetoclax responders in AML/MDS?	14
Survival prediction optimization of acute myeloid leukaemia based on T‐cell function‐related genes and plasma proteins	14
Transfusion of red cells from donors with hereditary haemochromatosis improve haemoglobin increments in patients	14
Prognostic impact of pretreatment cell‐free DNA concentration in newly diagnosed peripheral T‐cell lymphomas	14
Clinical and neurophysiological aspects of peripheral neuropathy in patients with myelodysplastic syndromes	14
Chimeric antigen receptor T‐cell therapy for mantle cell lymphoma with central nervous system involvement: Progress, but not perfect	14
The distribution and accumulation of the shortest telomeres in telomere biology disorders	14
Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights	14
Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study	14
Effect of peptide‐binding motif on survival of HLA‐haploidentical transplantation with post‐transplant cyclophosphamide	14
Demographic and clinical characteristics of acute myeloid leukaemia diagnosed and treated at the tertiary level in Afghanistan	14
Extended vincristine and dexamethasone pulse therapy may not be necessary for children with TCF3‐PBX1 positive acute lymphoblastic leukaemia	14
The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia	14
Up‐regulation of miR‐130a is related to leg ulcers in sickle cell anaemia	14
British Society for Haematology updated guidelines for the diagnosis and management of tumour lysis syndrome in adults and children with haematological malignancies: A focus on patient safety	14
Predicting therapy‐related myeloid neoplasms after CAR‐T with the Clonal Haematopoiesis Risk Score (CHRS)	14
A rare homozygous variant in TERT gene causing variable bone marrow failure, fragility fractures, rib anomalies and extremely short telomere lengths with high serum IgE	14
Single‐cell profiling of ineffective erythropoiesis in a mouse model of β‐thalassaemia intermedia	14
Temporal trends in relative survival of diffuse large B‐cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies	14
Acute chest syndrome in adult patients with sickle cell disease: The relationship with the time to onset after hospital admission	14
Biochemical screening of glucose‐6‐phosphate dehydrogenase deficiency in borderline cases: Complementary inputs of standardization enzymes and comparison with genetic status	14
t(9;12)(q22;p13) ETV6::SYK: A new recurrent cytogenetic aberration and tyrosine kinase gene fusion in myeloid or lymphoid neoplasms associated with eosinophilia	14
Two novel families with RUNX1 variants indicate glycine 168 as a new mutational hotspot: Implications for FPD/AML diagnosis	13
A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance	13
High‐dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study	13
Chronic refractory immune thrombocytopenia in adolescents and young adults	13
External validation and calibration of the HoLISTIC Consortium's advanced‐stage Hodgkin lymphoma international prognostic index (A‐HIPI) in the Brazilian Hodgkin lymphoma registr	13
Diagnosis, management and the burden of symptoms of mastocytosis from the physician's perspective: A nationwide study	13
First‐line immunotherapy with anti‐PD‐1 antibody for extranodal NK/T‐cell lymphoma: A retrospective study	13
Characterisation of children and adolescents with acute lymphoblastic leukaemia who presented without peripheral blood blasts at diagnosis	13
Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post‐CAR‐T‐cell therapy	13
A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies	13
Safe use of hydroxycarbamide in sickle cell disease patients hospitalized for painful vaso‐occlusive episodes during the randomized, open‐label HELPS study	13
Human leukocyte antigen evolutionary divergence influences outcomes of paediatric patients and young adults affected by malignant disorders given allogeneic haematopoietic stem cell transplantation fr	13
NGS ‐based targeted sequencing guides risk‐adapted and molecularly targeted therapy decisions in multiple myeloma	13
Reed–Sternberg‐like cells in central nervous system relapse of diffuse large B‐cell lymphoma	13
Metformin augments GPRC5D in multiple myeloma and enhances the efficacy of GPRC5D‐CAR T cells	13
Update on B‐cell maturation antigen‐directed therapies in AL amyloidosis	13
Are the current guidelines for identification of myelodysplastic syndrome with germline predisposition strong enough?	13
Baseline characteristics of Ghanaian children and adults enrolled in PIVOT , a randomised clinical trial of hydroxyurea in H	13
Cauda equina syndrome secondary to extramedullary erythropoiesis in a transfusion‐dependent thalassemia patient following treatment with luspatercept: A case report	13
Laboratory practice on detection of antiphospholipid antibodies: UK NEQAS blood coagulation survey—2024	13
Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation	13
Dimethyl fumarate ameliorates graft‐versus‐host disease by inhibiting T‐cell metabolism and immune responses through a reactive oxygen species‐dependent mechanism	13
Clinical features and prognostic model for viral encephalitis after allogeneic haematopoietic stem cell transplantation	12
Issue Information	12
Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response	12
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study	12
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study	12
Transient imaging changes accompany ‘spinal ICANS ’ following CAR T‐cell therapy for large B‐cell	12
Dutcher bodies and Russell bodies in a case of t(11;14) multiple myeloma	12
Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia	12
Benefit of repeatedCOVID‐19 vaccination for patients with B‐cell malignancies	12
Risk of febrile neutropenia in very elderly patients aged ≥80 years receiving their first cycle of R‐CHOP regimen: a nationwide real‐world study in Japan	12
Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T‐cell therapy	12
Expression of Concern: Effect of insulin‐like growth factor 1 on PHA‐stimulated cord blood mononuclear cell telomerase activity	12
Inflammatory profile of lower risk myelodysplastic syndromes	12
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma	12
Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and pa	12
The Russian invasion of Ukraine: Implications for haematologists	12
Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia	12
Everyone is entitled to his or her own opinion but not to their own facts*	12
Longitudinal evaluation of adverse events due to steroid use in primary immune thrombocytopenia: A population‐based study	12
Is there a role for eltrombopag drug levels in paediatric immune thrombocytopenia management?	12
Platelet count decline and high neutrophil count within the first day of admission for painful sickle cell vaso‐occlusive episodes predict severe complications	12
Chemotherapy‐induced thrombocytopenia: modern diagnosis and treatment	12
Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019	12
Nicotinamide enhances Treg differentiation by promoting Foxp3 acetylation in immune thrombocytopenia	12
Erratum	12
Reduced dose prednisone plus eltrombopag for the treatment of newly diagnosed adult primary immune thrombocytopenia: A prospective, multicentre, phase 2 clinical trial	12
	12
Paging all ENT specialists: Sinus manifestations of Erdheim–Chester disease	12
FISH‐ing for answers: Can genomic arrays add to our understanding of disease biology in low‐risk chronic lymphocytic leukaemia?	12
Quad‐class exposed/refractory myeloma is associated with short survival	11
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies	11
Effectiveness of in vivo T‐cell‐depleted regimen containing porcine anti‐lymphocyte globulin or rabbit anti‐thymocyte globulin in preventing acute graft‐versus‐host disease after haploidentical haemat	11